Quibim
Quibim is a Valencia, Spain-based AI medical imaging company that builds the QP-Insights® cloud radiomics platform and FDA/CE/UKCA-cleared Software as a Medical Device products (QP-Prostate, QP-Brain, QP-Liver, QP-Breast, QP-Lung) for hospitals, radiology departments, and biopharmaceutical companies worldwide.
- Company typePrivate
- Founded2015
- HeadquartersValencia, Spain
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Quibim does
Quibim is a Valencia, Spain-based healthtech company founded in 2012 that builds cloud-based radiomics and AI imaging biomarker solutions for precision medicine. Its core technology, the QP-Insights® platform, is a tissue-agnostic, web-based system that ingests, indexes, harmonizes, and stores large-scale medical imaging data (MRI, CT, PET/CT) and multi-omics datasets, standardizing image quality across equipment manufacturers. On top of this platform sit five regulated Software as a Medical Device products: QP-Prostate® (PI-RADS v2.1 compliant prostate MRI analysis), QP-Brain® (brain volumetry and white matter hyperintensity analysis), QP-Liver® (fat and iron quantification with automated liver segmentation), QP-Breast®, and QP-Lung®, each with FDA, CE, UKCA and (for QP-Prostate) Health Canada clearances. The company applies proprietary radiomics and deep feature extraction to support clinical research, biomarker discovery, and predictive analytics for survival, treatment response, and toxicity.
Quibim serves two distinct customer segments. Its primary commercial channel targets healthcare providers (hospitals, radiology departments, imaging centers) through direct enterprise sales and through OEM distribution partnerships with Philips (embedding QP-Prostate and QP-Brain in Philips' Advanced Visualization Workspace and BlueSeal MRI systems, with a 44% reading-time reduction cited at RSNA 2025) and with Aidoc (integrating QP-Prostate into the aiOS platform across 1,600+ hospitals). The second segment is biopharmaceutical companies, where Quibim operates value-based partnerships for patient stratification, treatment response prediction, and toxicity monitoring in clinical trials; named biopharma partners include Merck KGaA and Novartis. Revenue mechanics are quote-based, with recurring subscription-style SaMD licensing to hospitals and platform licensing to pharma. The company holds ISO 27001:2022, HIPAA and GDPR certifications and is venture-backed, having closed a $50 million Series A in January 2025 led by Asabys and Buenavista to fund US expansion, product development, and global partnerships.
Operationally, Quibim is led by co-founder and CEO Angel Alberich-Bayarri with co-founder Luis Martí Bonmatí serving as Founder and Scientific Advisor, alongside a commercial team including a CFO (Matthew Good), CSO (Kabir Mahajan), CCO (Peter Segers), and functional VPs across discovery, regulatory, business development, and customer success. The company has been expanding its ecosystem through partnerships with NVIDIA MONAI (model operationalization) and Vara (breast cancer screening AI distribution in Spain), and was selected in May 2026 as the only healthtech company for New York's strategic AI program.
Quibim firmographics
Firmographics- Name
- Quibim
- Legal name
- Quibim
- Website
- https://quibim.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Quibim is a Valencia, Spain-based AI medical imaging company that builds the QP-Insights® cloud radiomics platform and FDA/CE/UKCA-cleared Software as a Medical Device products (QP-Prostate, QP-Brain, QP-Liver, QP-Breast, QP-Lung) for hospitals, radiology departments, and biopharmaceutical companies worldwide.
- Ownership category
- akta.pro rank
Quibim industry classification
Industry- Product category
- Medical Imaging AI Software
- NAICS
- Software Publishers (5132), Scientific Research and Development Services (5417)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
Keywords
Where Quibim is headquartered
LocationHeadquarters
- HQ city
- Valencia
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
Quibim business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations, Others
Revenue model
- Medical Device Software (SaMD): Quibim commercializes FDA/CE/UKCA-cleared AI products (QP-Prostate, QP-Brain, QP-Liver) as Software as a Medical Device to healthcare providers. Revenue is generated through licensing of these diagnostic tools to hospitals and imaging centers.
- Life Sciences / Biopharma Services: Value-based partnerships with biopharma companies to accelerate drug development programs, including patient stratification, treatment response prediction, and toxicity monitoring using AI imaging biomarkers.
- Platform Licensing: Licensing of the QP-Insights® cloud platform and embedded AI models to pharmaceutical companies and research institutions for clinical studies and drug discovery applications.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Quibim product offering
Product offeringCore offering
Quibim develops and commercializes cloud-based AI software as a medical device (SaMD) for quantitative medical imaging analysis. Its QP-Insights® platform extracts radiomics and deep features from MRI, CT, and PET/CT images, while disease-specific products (QP-Prostate®, QP-Brain®, QP-Liver®, QP-Breast®, QP-Lung®) provide regulatory-cleared diagnostic support to healthcare providers and biopharma partners.
Product overview
Quibim is a healthtech company specializing in imaging biomarkers for precision medicine. The product portfolio consists of a cloud-based platform (QP-Insights®) with multiple AI-powered medical device software products: QP-Prostate® for prostate MRI analysis, QP-Brain® for brain volumetry and white matter analysis, QP-Liver® for liver disease quantification, QP-Breast® for breast cancer imaging, and QP-Lung® for lung imaging. The QP-Insights® platform serves as the foundational infrastructure that handles imaging data management, harmonization, indexing, storage, and multi-omics integration, while the individual QP products are specialized AI solutions that run on or integrate with this platform for specific disease applications in clinical and pharmaceutical settings.
Differentiator
Problem solved
Functional benefit
Brands
- QP-Prostate®: AI solution for prostate MRI analysis that revolutionizes the prostate MRI read by facilitating radiologist work, providing precise quantitative information and PI-RADS compliance.
- QP-Brain®
- QP-Liver®
- QP-Breast®
- QP-Lung®
- QP-Insights®
Products and services
- QP-Prostate® AI-powered prostate MRI analysis solution that integrates with PACS systems to provide automated PI-RADS v2.1 compliance evaluation, image quality assessment, and structured reports for prostate cancer detection. Designed for radiologists and healthcare providers performing prostate MRI reads.
- QP-Brain® Brain volumetry and white matter hyperintensity (WMH) analysis tool providing precise volume and morphometry calculations to support disease classification, progression monitoring, and neurological diagnosis. Targets radiologists and neurologists performing brain MRI analysis.
- QP-Liver® Liver disease management solution that quantifies fat and iron concentration to evaluate steatosis and iron overload, with automated whole abdomen and liver segmentation. Used by radiologists and hepatologists for liver imaging analysis.
- QP-Breast® AI-powered breast cancer imaging analysis solution in Quibim's product portfolio.
- QP-Lung® AI solution for lung imaging analysis in Quibim's product portfolio.
- QP-Insights® Web-based cloud platform for managing, storing, and analyzing large-scale multi-omics data and medical images for clinical studies and research projects involving AI and radiomics. Handles imaging data harmonization, links imaging data with EHR information, and supports embedded products. Targeted at hospitals, research institutions, and biopharma companies running clinical studies.
Quantifiable outcome
- Reduced manual segmentation time for liver disease analysis through automated whole abdomen and liver segmentation
- +2 more outcomes
Companies that use Quibim
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles2 records
Quibim technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability3 records
Feature6 records
Quibim partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered minor, core and flagship.
- VaraminorQuibim partnered with Germany's Vara to bring Europe's leading breast-cancer screening AI to Spain. This partnership expands Quibim's presence in the breast cancer diagnostics market through Vara's established screening AI technology.
- NVIDIA MONAIcorePartnership to operationalize medical imaging AI models through NVIDIA's MONAI framework. Quibim's AI capabilities are integrated via MONAI to help health systems scale imaging AI deployment across clinical workflows.
- AidoccoreAidoc partnered with Quibim to add Prostate MRI AI capabilities to its aiOS platform. The partnership enables health systems to access Quibim's QP-Prostate solution through Aidoc's established deployment infrastructure across 1,600+ hospitals.
- PhilipsflagshipQuibim partnered with Koninklijke Philips N.V. to integrate AI into prostate cancer diagnostics. Philips integrates Quibim's QP-Prostate and QP-Brain AI solutions into its Advanced Visualization Workspace (AVW) and BlueSeal MRI systems. At RSNA 2025, Philips announced expanded AI partnerships including disease-specific diagnostic capabilities for prostate cancer.
- Merck KGaAcorePartnership with Merck KGaA for AI imaging biomarker applications supporting pharmaceutical drug development programs. Quibim provides imaging analysis capabilities for patient stratification and treatment monitoring.
- NovartiscorePartnership with Novartis for AI-powered imaging analysis supporting pharmaceutical development programs. Collaboration focuses on integrating AI biomarkers into drug development workflows.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Quibim competitors and assessment
Company assessmentBroad incumbents
- Siemens Healthineers (AI-Rad Companion): Major imaging OEM offering AI-Rad Companion radiology AI suite across modalities. Competes broadly with Quibim across multi-organ AI imaging and represents the integrated-platform alternative to Quibim's modular approach.
- Philips (IntelliSpace AI): Global medical imaging OEM whose IntelliSpace AI / Advanced Visualization Workspace embeds Quibim's algorithms. Also a potential competitor as Philips broadens its own AI imaging portfolio.
Direct peers
- Aidoc: Israel/US AI imaging vendor operating the aiOS platform deployed across 1,600+ hospitals. Both a distribution partner (hosting QP-Prostate) and a direct competitor in AI-driven radiology workflow.
- Qure.ai: India/US AI imaging company with FDA-cleared algorithms for head CT, chest X-ray, and lung nodule detection. Competes with Quibim across the same hospital radiology AI buying motion.
- icometrix: Belgium-based AI imaging company focused on brain MRI quantification (icobrain) for multiple sclerosis and neurodegeneration. Direct competitor to QP-Brain in neurological image analysis and runs a similar SaaS-to-radiology model.
- Annalise.ai: Australia-based AI imaging vendor covering chest X-ray and CT triage/decision-support with broad modality coverage. Comparable multi-disease AI imaging portfolio and similar enterprise go-to-market.
- Nanox (Zebra Medical Vision): Imaging AI portfolio acquired from Zebra Medical Vision, offering FDA-cleared algorithms across multiple body parts. Competes in the same AI-radiology SaaS category as Quibim's QP-* product family.
- Paige.AI: US-based AI company applying deep learning to pathology and oncology imaging (Prostate, breast). Closely comparable in AI imaging biomarkers for cancer diagnostics and biopharma partnerships.
- Arterys (Tempus): Cloud-native AI imaging platform acquired by Tempus, offering cardiac, lung, and liver quantification. Direct overlap with QP-Insights as a cloud imaging-AI platform and with QP-Liver/QP-Lung modules.
- Perspectum: UK-based quantitative imaging company offering LiverMultiScan and brain MRI tools. Competes head-to-head with QP-Liver and QP-Brain and shares the radiomics-to-precision-medicine positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Quibim social profiles
Digital presenceQuibim compliance and trust
Trust signalCompliance3 records
Quibim financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quibim leadership team
Management profileNumber of profiles
Profiles15 records
Quibim funding detail
Funding detailFunding overview
Funding rounds12 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quibim M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quibim
What does Quibim do?
Quibim develops and commercializes cloud-based AI software as a medical device (SaMD) for quantitative medical imaging analysis. Its QP-Insights® platform extracts radiomics and deep features from MRI, CT, and PET/CT images, while disease-specific products (QP-Prostate®, QP-Brain®, QP-Liver®, QP-Breast®, QP-Lung®) provide regulatory-cleared diagnostic support to healthcare providers and biopharma partners.
Is Quibim a public or private company?
Quibim is a private company. It is classified as venture growth investor backed and is currently operating.
When was Quibim founded?
Quibim was founded in 2015. It employs 51 to 100 people.
Where is Quibim based?
Quibim is headquartered in Valencia, Spain, in the Europe region.
How does Quibim make money?
Three revenue lines are on record. Medical Device Software (SaMD) is the primary driver. The others are life Sciences / Biopharma Services and platform Licensing.
Who are Quibim's main competitors?
Broad incumbents on record are Siemens Healthineers (AI-Rad Companion) and Philips (IntelliSpace AI). Direct peers are Aidoc, Qure.ai, icometrix, Annalise.ai, Nanox (Zebra Medical Vision), Paige.AI, Arterys (Tempus) and Perspectum.
Does Quibim have an API?
No public API is recorded for Quibim.
What industry is Quibim in?
Quibim's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 5132 and its SIC code is 3841.